Quick Answer
ADMA BIOLOGICS, INC. reported Net Income Loss of $146.93 million for the year ending 2025.
- ADMA BIOLOGICS, INC. showed a decrease of -25.7% in Net Income Loss from 2024 to 2025.
- This data is from ADMA BIOLOGICS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$3.24 million | Q2 2013: -$4.90 million | Q3 2013: -$2.69 million | Q1 2014: -$5.90 million | Q2 2014: -$3.96 million | Q3 2014: -$3.38 million | Q1 2015: -$3.61 million | Q2 2015: -$4.68 million | Q3 2015: -$5.10 million | Q1 2016: -$4.61 million | Q2 2016: -$6.01 million | Q3 2016: -$4.33 million | Q1 2017: -$6.54 million | Q2 2017: -$9.04 million | Q3 2017: -$15.20 million | Q1 2018: -$17.82 million | Q2 2018: -$14.75 million | Q3 2018: -$15.14 million | Q4 2018: -$18.04 million | Q1 2019: -$13.07 million | Q2 2019: -$13.21 million | Q3 2019: -$11.44 million | Q1 2020: -$19.25 million | Q2 2020: -$20.18 million | Q3 2020: -$16.92 million | Q1 2021: -$18.38 million | Q2 2021: -$18.91 million | Q3 2021: -$17.71 million | Q1 2022: -$25.01 million | Q2 2022: -$13.76 million | Q3 2022: -$14.90 million | Q1 2023: -$6.79 million | Q2 2023: -$6.37 million | Q3 2023: $2.57 million | Q1 2024: $17.81 million | Q2 2024: $32.06 million | Q3 2024: $35.91 million | Q1 2025: $26.90 million | Q2 2025: $34.22 million | Q3 2025: $36.43 million.
- Over the full 15 years of available data (2011 to 2025), ADMA BIOLOGICS, INC.'s Net Income Loss has grown by 2,588.9%.
- Historical annual values: Fiscal year 2025: $146.93 million | Fiscal year 2024: $197.67 million | Fiscal year 2023: -$28.24 million | Fiscal year 2022: -$65.90 million | Fiscal year 2021: -$71.65 million | Fiscal year 2020: -$75.75 million | Fiscal year 2019: -$48.28 million | Fiscal year 2018: -$65.74 million | Fiscal year 2017: -$43.76 million | Fiscal year 2016: -$19.52 million | Fiscal year 2015: -$17.97 million | Fiscal year 2014: -$16.81 million | Fiscal year 2013: -$15.53 million | Fiscal year 2012: -$7.30 million | Fiscal year 2011: -$5.90 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: